Peptides DB
Research-centric peptide and protocol reference hub

HGH Fragment 176-191 (HGH Frag) record · updated 7h ago

Metabolic & appetiteSkin & aestheticsGrade C · preclinicalResearch use only
All 1 studiesJump to the evidenceCompare
What is HGH Fragment 176-191 (HGH Frag) used for?

HGH Fragment 176-191 is a synthetic C-terminal fragment of human growth hormone studied for its lipolytic (fat-burning) effects without the growth-promoting actions of full GH.

Primarily researched for · Metabolic & appetite

Development stage

where HGH Fragment 176-191 (HGH Frag) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 5 registered trials. It describes the research record, not a recommendation.

Identity
NameHGH Fragment 176-191 (HGH Frag)
Full name—
Sequence—
ClassWeight Loss
Research levelModerate Research
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Metabolic & appetite: Healing 0.0, Muscle 1.0, Metabolic 4.0, Neuro 0.0, Sleep 0.0, Immune 0.0, Skin 2.0Muscle & body comp — 1.0 / 5Metabolic & appetite — 4.0 / 5Skin & aesthetics — 2.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin0.01.04.00.00.00.02.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies1
Human / animal / cellular0 / 0 / 0
Highest trial phase—
Years covered—
Latest study14d ago
Publication history
No publication years on file
——
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

1 rowOpen in the library →
StudyTypeYearSummary depth
Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis.
Finding10.5% of samples declared to contain substances used in PCT, n=601.
——Full text read0.80